Compare Aurobindo Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DR. REDDYS LAB - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DR. REDDYS LAB AUROBINDO PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 18.6 38.5 48.2% View Chart
P/BV x 4.0 5.3 76.3% View Chart
Dividend Yield % 0.3 0.5 52.0%  

Financials

 AUROBINDO PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
DR. REDDYS LAB
Mar-20
AUROBINDO PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs8303,363 24.7%   
Low Rs5272,352 22.4%   
Sales per share (Unadj.) Rs333.91,054.2 31.7%  
Earnings per share (Unadj.) Rs40.4121.9 33.1%  
Cash flow per share (Unadj.) Rs51.8190.2 27.2%  
Dividends per share (Unadj.) Rs2.5025.00 10.0%  
Dividend yield (eoy) %0.40.9 42.1%  
Book value per share (Unadj.) Rs237.1938.7 25.3%  
Shares outstanding (eoy) m585.91166.17 352.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.02.7 75.0%   
Avg P/E ratio x16.823.4 71.7%  
P/CF ratio (eoy) x13.115.0 87.3%  
Price / Book Value ratio x2.93.0 94.0%  
Dividend payout %6.220.5 30.2%   
Avg Mkt Cap Rs m397,569474,831 83.7%   
No. of employees `00017.921.7 82.5%   
Total wages/salary Rs m25,84933,802 76.5%   
Avg. sales/employee Rs Th10,956.98,091.0 135.4%   
Avg. wages/employee Rs Th1,447.71,561.3 92.7%   
Avg. net profit/employee Rs Th1,324.3935.8 141.5%   
INCOME DATA
Net Sales Rs m195,636175,170 111.7%  
Other income Rs m1,5536,206 25.0%   
Total revenues Rs m197,189181,376 108.7%   
Gross profit Rs m39,51924,421 161.8%  
Depreciation Rs m6,68011,348 58.9%   
Interest Rs m2,626983 267.1%   
Profit before tax Rs m31,76718,296 173.6%   
Minority Interest Rs m270-   
Prior Period Items Rs m0561 0.0%   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,269-1,403 -518.1%   
Profit after tax Rs m23,64520,260 116.7%  
Gross profit margin %20.213.9 144.9%  
Effective tax rate %22.9-7.7 -298.4%   
Net profit margin %12.111.6 104.5%  
BALANCE SHEET DATA
Current assets Rs m153,645125,991 121.9%   
Current liabilities Rs m120,42972,141 166.9%   
Net working cap to sales %17.030.7 55.2%  
Current ratio x1.31.7 73.1%  
Inventory Days Days13573 185.0%  
Debtors Days Days64105 60.8%  
Net fixed assets Rs m103,90983,854 123.9%   
Share capital Rs m586831 70.5%   
"Free" reserves Rs m138,322155,157 89.1%   
Net worth Rs m138,908155,988 89.1%   
Long term debt Rs m1,8001,304 138.0%   
Total assets Rs m264,544232,253 113.9%  
Interest coverage x13.119.6 66.8%   
Debt to equity ratio x00 155.0%  
Sales to assets ratio x0.70.8 98.1%   
Return on assets %9.99.1 108.6%  
Return on equity %17.013.0 131.1%  
Return on capital %23.812.6 189.0%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31684,193 115.6%   
Fx outflow Rs m40,58939,616 102.5%   
Net fx Rs m56,72744,577 127.3%   
CASH FLOW
From Operations Rs m16,22029,841 54.4%  
From Investments Rs m-28,768-4,923 584.4%  
From Financial Activity Rs m19,191-25,159 -76.3%  
Net Cashflow Rs m6,656-266 -2,502.4%  

Share Holding

Indian Promoters % 54.1 25.5 212.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 5.4 147.2%  
FIIs % 27.7 35.3 78.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.2 15.3 66.7%  
Shareholders   69,601 75,885 91.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   VENUS REMEDIES  ORCHID PHARMA  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Dives Over 1,100 Points, Dow Futures Down by 119 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 1,148 points, down 2.4% at 47,683 levels.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 19, 2021 02:48 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS